Synthroid

Product manufactured by Abbvie Inc.

Application Nr Approved Date Route Status External Links
NDA021402 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Hypothyroidism Synthroid Is Indicated As A Replacement Therapy In Primary (Thyroidal), Secondary (Pituitary), And Tertiary (Hypothalamic) Congenital Or Acquired Hypothyroidism. Pituitary Thyrotropin (Thyroid‑stimulating Hormone, Tsh) Suppression Synthroid Is Indicated As An Adjunct To Surgery And Radioiodine Therapy In The Management Of Thyrotropin-Dependent Well-Differentiated Thyroid Cancer. Limitations Of Use: Synthroid Is Not Indicated For Suppression Of Benign Thyroid Nodules And Nontoxic Diffuse Goiter In Iodine-Sufficient Patients As There Are No Clinical Benefits And Overtreatment With Synthroid May Induce Hyperthyroidism [See Warnings And Precautions (5.4) ] . Synthroid Is Not Indicated For Treatment Of Hypothyroidism During The Recovery Phase Of Subacute Thyroiditis. Synthroid Is Levothyroxine Sodium (T4) Indicated For: Hypothyroidism: As Replacement Therapy In Primary (Thyroidal), Secondary (Pituitary), And Tertiary (Hypothalamic) Congenital Or Acquired Hypothyroidism. (1) Pituitary Thyrotropin (Thyroid‑stimulating Hormone, Tsh) Suppression: As An Adjunct To Surgery And Radioiodine Therapy In The Management Of Thyrotropin-Dependent Well-Differentiated Thyroid Cancer. (1) Limitations Of Use: - Not Indicated For Suppression Of Benign Thyroid Nodules And Nontoxic Diffuse Goiter In Iodine-Sufficient Patients. - Not Indicated For Treatment Of Hypothyroidism During The Recovery Phase Of Subacute Thyroiditis.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Levothyroxine Sodium LEVOTHYROXINE SODIUM ZINC3830993

Comments